The metabolic syndrome is associated with an increase in the activation of the renin angiotensin system, whose inhibition reduces the incidence of new-onset diabetes. Importantly, angiotensin II (AngII), independently of its vasoconstrictor action, causes b-cell inflammation and dysfunction, which may be an early step in the development of type 2 diabetes. The aim of this study was to determine how AngII causes b-cell dysfunction. Islets of Langerhans were isolated from C57BL/6J mice that had been infused with AngII in the presence or absence of taurineconjugated ursodeoxycholic acid (TUDCA) and effects on endoplasmic reticulum (ER) stress, inflammation, and b-cell function determined. The mechanism of action of AngII was further investigated using isolated murine islets and clonal b cells. We show that AngII triggers ER stress, an increase in the messenger RNA expression of proinflammatory cytokines, and promotes b-cell dysfunction in murine islets of Langerhans both in vivo and ex vivo. These effects were significantly attenuated by TUDCA, an inhibitor of ER stress. We also show that AngII-induced ER stress is required for the increased expression of proinflammatory cytokines and is caused by reactive oxygen species and IP3 receptor activation. These data reveal that the induction of ER stress is critical for AngII-induced b-cell dysfunction and indicates how therapies that promote ER homeostasis may be beneficial in the prevention of type 2 diabetes. (Endocrinology 158: 3162-3173, 2017) E levated blood pressure due to increased activation of the renin angiotensin system (RAS) is an important feature of the metabolic syndrome. This constitutes a series of metabolic disorders that increase the risk of developing type 2 diabetes and cardiovascular disease. Importantly, the pharmacological inhibition of RAS reduces the incidence of new-onset type 2 diabetes in highrisk populations (1-3), and RAS blockade in several animal models of diabetes improves pancreatic b-cell function (4-8). Conversely, the infusion of angiotensin II (AngII) into mice causes b-cell dysfunction (9-11). As the components of the RAS system have been detected in islets and this "local" RAS plays an important role in regulating islet mass and function (7, 9), the effects of RAS blockade in vivo are likely mediated by inhibiting locally produced AngII.
levated blood pressure due to increased activation of the renin angiotensin system (RAS) is an important feature of the metabolic syndrome. This constitutes a series of metabolic disorders that increase the risk of developing type 2 diabetes and cardiovascular disease. Importantly, the pharmacological inhibition of RAS reduces the incidence of new-onset type 2 diabetes in highrisk populations (1) (2) (3) , and RAS blockade in several animal models of diabetes improves pancreatic b-cell function (4) (5) (6) (7) (8) . Conversely, the infusion of angiotensin II (AngII) into mice causes b-cell dysfunction (9) (10) (11) . As the components of the RAS system have been detected in islets and this "local" RAS plays an important role in regulating islet mass and function (7, 9) , the effects of RAS blockade in vivo are likely mediated by inhibiting locally produced AngII.
The detrimental effects of AngII on b-cell function were largely attributed to vasoconstriction, resulting in decreased delivery of glucose to pancreatic b cells (12) (13) (14) . However, it has recently been shown that AngII infusion in mice causes b-cell dysfunction independently of AngII's effect on blood pressure (11) . In support of this, the treatment of either isolated human or rodent islets with AngII also causes b-cell dysfunction (9) (10) (11) . The damaging effects of AngII on b-cell function, both in vivo and in vitro, have been ascribed to an increase in the expression of proinflammatory cytokines, in particular interleukin 1b (Il-1b) (11) , and there is a growing body of evidence indicating that inflammation is important in the development of b-cell dysfunction in type 2 diabetes (15) (16) (17) . Endoplasmic reticulum (ER) stress is also associated with the loss of b-cell function and viability in type 2 diabetes (18) (19) (20) (21) . This stress is sensed by the ER transmembrane proteins: PKR-like ER kinase (PERK), activating transcription factor 6, and inositol requiring enzyme 1 (IRE1)a, which activate an adaptive response called the unfolded protein response (UPR) (21) (22) (23) . If the UPR is unable to alleviate ER stress, b-cell dysfunction and death can occur through the chronic activation of a UPR, which activates a number of proapoptotic and proinflammatory signaling pathways (16, 23, 24) . Given that AngII also increases the expression of proinflammatory cytokines and causes b-cell dysfunction (11), we hypothesized that ER stress may play an important role in AngII-mediated b-cell inflammation and dysfunction.
Materials and Methods

Cell culture
Mouse insulinoma 6 (MIN6) cells (25) were used between passages 25 and 35 at~80% confluence and cultured as previously described (26) .
Islet isolation
Pancreatic islets were isolated from adult C57BL/6J mice (Animal Resources Centre, Perth, Australia). Briefly, the pancreas was inflated by injecting 3 mL RPMI 1640 (Invitrogen, Waltham, MA) containing 1 mg/mL collagenase (Sigma-Aldrich, St. Louis, MO) through the common pancreatic duct and the pancreas excised. Islets were then isolated as previously described (26) .
Animal experimentation
All experiments were approved by the Animal Ethics Committee of Royal Melbourne Institute of Technology University (1504). Male C57BL/6J mice (10 weeks of age) obtained from the Animal Resources Centre) were kept at 22 6 1°C on a 12-hour light/dark cycle. All mice were fed standard mouse chow and water ad libitum. After 1 week of acclimatization, the mice were randomly assigned to three groups: (1) sham [control mice infused with phosphate-buffered saline; n = 8], (2) AngII (mice infused with human AngII, dissolved in sterile 13 phosphate-buffered saline, at 416 ng$kg 21 $min 21 using subcutaneous ALZET mini-osmotic pumps for 2 weeks; n = 8), or (3) AT [mice infused with AngII with daily intraperitoneal injection of taurine-conjugated ursodeoxycholic acid (TUDCA) at 150 mg$kg 21 
$d
21 for 2 weeks; n = 8]. Human AngII ($93% high-performance liquid chromatography) was purchased from Sigma. The body weight and plasma glucose levels were recorded three times weekly during the experiment. Systolic blood pressure was measured using the CODA tail-cuff blood pressure system (ADInstruments Pty Ltd., Sydney, Australia).
For glucose tolerance tests (2.5 g glucose/kg body weight, intraperitoneally), mice were fasted for 5 hours prior to blood samples being collected via the tail vein and blood glucose concentration determined using a glucometer (AccuCheck Proforma Nano; Roche, Basel, Switzerland). For insulin measurements, blood samples were centrifuged (2000 rpm, 2 minutes at 4°C) and the plasma insulin concentrations measured by enzyme-linked immunosorbent assay (Linco Research, St. Louis, MO) in collaboration with the Department of Physiology, Monash University, Melbourne. Mice were euthanized with CO 2 . The disposition index, a composite measure of b-cell function (27) , was also calculated using the following formula: ΔI 0-30 /ΔG 0-30 3 1/ fasting insulin.
Western blotting and immunohistochemistry
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blotting were performed as previously described (28) Transfection, RNA isolation, and quantitative polymerase chain reaction analyses Silencer Select small interfering RNAs (siRNAs) against Ire (cat. no. S95857) and Xbp (cat. no. S76114) were purchased from Ambion oligos (Thermo Scientific, Waltham, MA). siRNA oligos were transfected using Lipofectamine RNAiMAX (Thermo Scientific) according to the manufacturer's protocol. Total RNA was isolated using the ReliaPrep RNA Cell Miniprep System (Promega, Madison, WI). Reverse transcription was carried out using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA). Quantitative polymerase chain reaction was carried out using the SYBR Green PCR Master Mix (Applied Biosystems) using primers described in Supplemental Table 1 . The gene expression from each sample was analyzed in duplicate and normalized against the housekeeper 18S. All reactions were performed on the Rotor-Gene Q (Qiagen, Hilden, Germany). The results are expressed as relative gene expression using the DD threshold cycle method (29) .
Glucose-stimulated insulin secretion
Isolated islets were cultured overnight in RPMI 1640 medium supplemented with L-glutamine (20 mmol/L) and fetal bovine serum (5%). Glucose-stimulated insulin secretion (GSIS) was performed as previously described (28) . Insulin enzyme-linked immunosorbent assay was performed as described previously.
Quantification of superoxide levels
Superoxide levels were measured using L-012 (Tocris Bioscience, Bristol, UK) enhanced chemiluminescence as previously described (30) . MIN6 cells were plated on a 96-well Optiplate (PerkinElmer, Waltham, MA), incubated with 100 mmol/L L-012, and luminescence was measured using a BMG Clariostar plate reader (BMG Labtech, Ortenberg, Germany).
Statistical analysis
Data are expressed as mean 6 standard error, unless otherwise stated. Data were analyzed by one-way analysis of variance followed by Tukey post hoc test for multiple comparisons between means using Prism 6 (GraphPad Software, La Jolla, CA). Differences were considered statistically significant at P , 0.05.
Results
Angiotensin II induces ER stress and impairs b-cell function in mouse islets of Langerhans
To investigate the role of ER stress on AngIIdependent b-cell dysfunction, mouse islets of Langerhans were treated with AngII for 96 hours in the presence or absence of TUDCA, a chemical chaperone that inhibits ER stress (31) . AngII caused b-cell dysfunction as demonstrated by a marked increase of basal insulin secretion and a significant decrease in the stimulatory index compared with control islets, reflecting the loss of GSIS ( Fig. 1a and 1b ). This correlated with a decrease in the messenger RNA (mRNA) expression of glucokinase (Gk) (Fig. 1c) , whereas the mRNA expression of glucose transporter 2 (Glut2) and pancreatic and duodenal homeobox 1 (Pdx1) were increased (Fig. 1c) . AngII treatment also significantly increased the expression of the proinflammatory cytokines Il-1b and tumor necrosis factor a (Tnf-a) (Fig. 1d) . However, no significant changes in monocyte chemotactic protein 1 (Mcp-1) were detected. Importantly, AngII caused a marked increase in the expression of markers of ER stress (Fig. 1e ), including BiP(also known as Grp78), the spliced form of X-box binding protein 1 (Xbp1s), endoplasmic reticulum oxidoreductin 1 (Ero1l), peptidyl-prolyl cis-trans isomerase (Fkbp11), ER degradation enhancing a-mannosidaselike protein (Edem), activating transcription factor 4 (Atf4), and the proapoptotic transcription factor C/EBP homologous protein [Chop (also known as Gadd153)] (32, 33). The coadministration of TUDCA with AngII significantly restored b-cell function, as demonstrated by a reduction in basal insulin secretion (Fig. 1a) , an improved stimulatory index (Fig. 1b) , and the restoration of glucokinase expression to control levels (Fig. 1c) . TUDCA also significantly decreased the expression of the proinflammatory cytokines Il-1b and Tnf-a (Fig. 1d ) and all the markers of ER stress investigated (Fig. 1e) . Thus, AngII causes b-cell dysfunction, ER stress, and inflammation in mouse islets of Langerhans, and these effects occur independently of AngII's systemic vasoconstrictive effects. Moreover, as TUDCA counteracts the effects of AngII, it is likely that the deleterious effects of AngII treatment observed here are mediated through ER stress.
ER stress precedes the induction of proinflammatory cytokines in AngII-treated MIN6 cells and islets of Langerhans
We initially investigated the efficacy of using the pancreatic b-cell line MIN6 as a model to further investigate AngII-induced ER stress and inflammation. MIN6 cells were treated with AngII or thapsigargin, a pharmacological inducer of ER stress, in the presence or absence of TUDCA (Supplemental Fig. 1 ). As observed in islets, AngII treatment caused ER stress and an increase in the expression of Il-1b, which was inhibited by TUDCA. Thapsigargin also evoked a UPR and increased the expression of Il-1b.
To investigate the temporal relationship between AngII-induced ER stress and the expression of proinflammatory cytokines, MIN6 cells were treated with AngII for up to 96 hours, and the induction of ER stress and the expression of Il-1b, Tnf-a, and Mcp-1 were monitored. AngII rapidly induced ER stress (within 2 hours) as determined by the phosphorylation status of IRE1a, PERK, and PERK's substrate eIF2a, as well as an increase in the expression of BiP, ATF4, CHOP, and Xbp1s ( Fig. 2a and 2b) . AngII increased the expression of thioredoxin interacting protein (TXNIP) (16) (Fig. 2b) at 6 hours and the expression of the proinflammatory cytokine Il-1b and Tnf-a mRNA by 6 hours and 48 hours, respectively (Fig. 2c) . No changes in the expression of Mcp1 were detected (Fig. 2c) . AngII treatment of mouse islets also caused an increase in the expression of Xbp1s, Atf4, and Chop, which preceded an increase in the expression of Il-1b and Tnfa (Fig. 2d) .
Therefore, the occurrence of ER stress precedes an increase in the expression of the proinflammatory cytokines, providing evidence that AngII-induced ER stress may promote inflammation in b cells.
The role of PERK and IRE1a in AngII-induced expression of the proinflammatory cytokines
To determine how ER stress increases the expression of the proinflammatory cytokines, we investigated the effect of a selective inhibitor of PERK, GSK2606414 (PERKi), and siRNA-mediated knockdown of Ire1a or Xbp1 on AngII-induced Il-1b expression. GSK2606414 (PERKi) inhibited AngII-induced phosphorylation of eIF2a (Fig. 3a) and expression of ATF4, CHOP (Fig.  3a) , Txnip (Fig. 3b) , and, importantly, Il-1b (Fig. 3b) . (Fig. 3c) . Importantly, siRNA-mediated knockdown of Ire1a or Xbp1 also inhibited AngII-evoked increases in Txnip and Il-1b expression (Fig. 3d) . These results provide evidence that both PERK and IRE1a are required for AngII to induce a proinflammatory response.
AngII-induced ER stress is dependent upon both IP3 receptor and NADPH oxidase activation AngII-induced ER stress and inflammation are dependent on angiotensin 1 receptor (AT1R) activation as irbesartan, an AT1R antagonist, attenuated both AngII-induced ER stress and Il-1b expression (Supplemental Fig. 2 ). The AT1R classically couples to Gq/11 and activates NADPH oxidase and phospholipase-C, resulting in an increase in IP3 and reactive oxygen species (ROS) (34, 35) . IP3 stimulates ER calcium release (34) , and ROS has been shown to sensitize the IP3 receptor (IP3R) (36) . As a decrease in ER calcium can induce ER stress (26), we investigated whether the effects of AngII were mediated by an IP3R-dependent mechanism. MIN6 cells were treated with AngII in the presence or absence of selective IP3 receptor antagonists, 2-aminoethoxydiphenyl borate and xestospongin-C, which inhibited AngII-induced ER stress as determined by a significant decrease in eIF2a phosphorylation, as well as the expression of ATF4 and CHOP (Fig. 4a) . Therefore, AngII-induced ER stress requires IP3R activation, indicating that AngII-induced ER stress is likely to be mediated by a decrease in ER calcium. However, for reasons that are unclear, treatment of cells with AngII in the presence of xestospongin-C for 6 hours potentiated AngII-induced eIF2a phosphorylation (Fig. 4a) .
To investigate the role of ROS, changes in superoxide production in MIN6 cells in response to AngII in the presence or absence of the AT1R antagonist irbesartan, as well as two selective inhibitors of NADPH oxidase, apocyin and diphenyleneiodonium (DPI), were determined (Fig. 4b) . As anticipated, AngII increased superoxide levels, and this was inhibited by apocynin (at 10 and 300 mM), DPI, and irbesartan (Fig. 4b) . Importantly, apocynin or DPI also inhibited AngII-induced ER stress as determined by the phosphorylation of eIF2a and the expression of ATF4 and CHOP (Fig. 4c) . These data provide evidence that ROS is required for AngII-induced ER stress. Given that IP3R activation is also required, it is possible that ROS promotes ER stress by sensitizing the IP3R (36) .
High glucose potentiates AngII-induced ER stress
To investigate the effect of glucose concentration on AngII-induced ER stress, MIN6 cells were incubated at either low (5.5 mM) or high (25 mM) glucose and the effect of AngII on ER stress determined. AngII treatment of MIN6 cells incubated at low glucose caused a significant increase in the expression of CHOP and ATF4, which marks the presence of ER stress. Interesting, incubation at high glucose (25 mM) potentiated the effect of AngII on ER stress (Supplemental Fig. 3a) . These experiments were repeated using isolated murine islets, and similar results were obtained (Supplemental Fig. 3b) . Thus, high glucose potentiates the effects of AngII on ER stress.
AngII infusion of mice causes ER stress and an increase in the expression of proinflammatory cytokines in pancreatic islets
To assess whether a chronic elevation in AngII caused ER stress in islets in vivo and whether this was important in the induction of proinflammatory cytokines, mice were infused with AngII for 2 weeks with or without the coadministration of TUDCA. Following AngII infusion, mice displayed a marked impairment of glucose tolerance ( Fig. 5a and 5b) together with elevated levels of fasting plasma insulin (Fig. 5c) , likely due to the known detrimental effects of AngII on insulin sensitivity (37) . Interestingly, there was also evidence of b-cell dysfunction as determined by a decrease in the disposition index (Fig. 5d) . The coadministration of TUDCA improved glucose tolerance, reduced plasma insulin levels ( Fig. 5a  and 5c ), and rescued b-cell function (Fig. 5d ). All these effects occurred independently of changes in body weight, adiposity, or a sustained increase in systolic blood pressure ( Supplemental Fig. 4) . Importantly, islets isolated from these AngII-infused animals showed signs of ER stress, as evidenced by an increase in the expression of Xbp1s, Fkbp11, Ero1l, Edem, Atf4, Chop, and Txnip (Fig. 5e) . However, no change in the expression of BiP, an adaptive marker of the UPR, was detected (Fig. 5e) . Importantly, Il-1b and Tnf-a expression was also augmented by AngII infusion (Fig. 5f) . Interestingly, as observed in isolated islets, AngII caused an increase in Pdx1 and Glut2 expression but a decrease in glucokinase expression (Fig. 5g) . The coadministration of TUDCA inhibited AngII-stimulated increase in the expression of: markers of ER stress (Fig. 5e) ; the proinflammatory cytokines (Fig. 5f) ; and the markers of b-cell function (Fig. 5g) . Taken together, these data provide evidence that in vivo AngII causes ER stress and that this increases the production of proinflammatory cytokines in islets.
To determine whether macrophages were present in islets isolated from AngII-treated mice, we looked for the presence of F4/80, a macrophage-specific marker, by quantitative polymerase chain reaction (Supplemental Fig. 5 ). Although F4/80 mRNA was detected in islets, its expression was unchanged by AngII, indicating the macrophages are unlikely to be the source of the proinflammatory cytokines.
Discussion
This study provides strong evidence that AngII causes ER stress to b cells/islets both in vitro and in vivo and that this results in a proinflammatory phenotype and b-cell dysfunction. In addition, we provide an insight into how AngII causes ER stress (Fig. 6) . We show that at high glucose, AngII, via AT1R activation, promotes IP3R activation and an increase in ROS. This, likely via a decrease in ER calcium, results in ER stress and an increase in the expression of proinflammatory cytokines mediated by the activation of PERK and IRE1a.
Although inflammation and the UPR are protective responses, chronic inflammation and/or UPR activation are associated with the pathogenesis of many diseases, including type 2 diabetes (23). Indeed, chronic inflammation has been implicated in b-cell dysfunction in type 2 diabetes, and treatment with either anakinra, an IL-1 receptor antagonist, or anti-IL-1b antibodies improves b-cell function, improves glycemic control, and reduces inflammation (38) (39) (40) . Moreover, IL-1b antagonism protects against the deleterious effects of AngII on islet function in high-fat diet-fed mice (11) . Thus, inflammation is a key mediator of AngII-induced b-cell dysfunction (11) . A role for ER stress in AngII-mediated inflammation has recently been shown in other cell types/ tissues (41-43), yet the mechanism by which this occurs had not been fully explored. In this study, we demonstrate that AngII-stimulated increase in proinflammatory cytokine expression in islets and b cells is caused by ER stress as: (1) Il-1b and Tnf-a expression is inhibited by TUDCA; (2) Il-1b expression is inhibited by inhibition/reduced expression of PERK and IRE1a/XBP1; (3) ER stress precedes an increase in the expression of Il-1b and Tnf-a; and (4) thapsigargin increases the expression of Il-1b and Tnf-a. This ER stressinduced increase in cytokine expression may be mediated by TXNIP, promoted by the activation of PERK and IRE1a as: (1) pharmacologically induced ER stress increases Il-1b mRNA expression through an increase in TXNIP expression, stimulated by the activation of PERK and IRE1 (16, 44) ; (2) AngII increases Txnip expression via a PERK-and IRE1a-dependent mechanism (Fig. 3) ; and (3) Txnip precedes the expression of Tnf-a and Il-1b and is inhibited by TUDCA.
AngII-induced ER stress is prevented by IP3R inhibition (Fig. 4) . Intriguingly, inhibitors of NADPH oxidase or the IP3R inhibit AngII-induced ER stress. As ER calcium depletion is known to cause ER stress (26, (45) (46) (47) (48) and ROS can potentiate IP3-dependent calcium release (36) , ER calcium depletion is the likely cause of AngII-induced ER stress.
We show that chronic AngII treatment causes a decrease in b-cell function both in vitro and in vivo as evaluated by a loss of GSIS caused by an increase in the release of insulin at a lower threshold of glucose (Figs. 1  and 5 ). Similar results have been observed in rodent and human islets chronically treated with AngII and in highfat diet-fed mice infused with AngII (11) . Interestingly, the loss of GSIS observed in this study was associated with decreased glucokinase expression (Figs. 1 and 6 ), a protein that sets the threshold for GSIS (49, 50) . As the expression of glucokinase and GLUT2 is positively related to the state of differentiation of the b cells and their expression is stimulated by PDX1 (51) (52) (53) , it is surprising that AngII increases Pdx1 and Glut2 expression both in vitro and in vivo (Figs. 1 and 6 ). However, we detected no change in PDX1 protein expression (results not shown). Thus, the significance of these changes in mRNA expression are unclear.
The components of the RAS system are expressed in islets, and these are upregulated in animal models of diabetes. Thus, locally generated AngII rather than systemic AngII likely plays an important role in islet inflammation and ultimately b-cell dysfunction in type 2 diabetes (7, 9, 54) . Interestingly, the AT1R antagonist losartan reduced high glucose-induced ER stress and decreased b-cell function in human islets (55) . Moreover, the administration of losartan to db/db mice improves islet function and mass, as well as delays the onset of diabetes, without affecting insulin sensitivity (7) . Thus, high glucose-induced ER stress and b-cell dysfunction are, at least in part, mediated by AngII acting via the AT1R. Interestingly, we found that high glucose potentiated the effects of AngII on ER stress in MIN6 cells and murine islets. In addition, AngII exacerbates palmitateinduced ER stress in MIN6 cells (unpublished results). Therefore, hyperglycemia and/or obesity may potentiate the deleterious effect of increased local AngII on b-cell function by exacerbating ER stress.
Together, these findings provide evidence that ER stress is a critical link between AngII and the induction of proinflammatory cytokines and that this may represent an initiating and/or early step in the development of b-cell dysfunction in type 2 diabetes. Disclosure Summary: The authors have nothing to disclose.
